Zoeti Librela News Today

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages ZTS Investors with Substantial Losses and Persons with Knowledge Who May Be Able to Assist...

This newsletter is a summary of the antitrust developments we think are most interesting to your business. Thomas Masterman, partner based in London, is our editor this month. He has...

The European Commission announced on Tuesday that it has initiated an investigation into whether Zoetis Inc (NYSE: ZTS hindered the market launch of a…

The European Commission launches probe into Zoetis over alleged market interference in dog pain medication launch. Focus on Zoetis' Librela monoclonal antibody for osteoarthritis pain relief in dogs raises antitrust concerns.

The European Commission announced on Tuesday that it has initiated an investigation into whether Zoetis Inc (NYSE: ZTS hindered the market launch of a competing pain medication for dogs. Zoetis’ Librela is the first and only monoclonal antibody medicine approved in Europe to treat pain associated with osteoarthritis in dogs. The medicine is administered monthly and offers a novel pain relief option, particularly relevant for older dogs. The European Commission said that Zoetis, while work...

By Foo Yun Chee and Bart H. Meijer (Reuters) -EU antitrust regulators have started an investigation into whether Zoetis blocked the market launch of a rival pain medicine for dogs, the European Commission said on Tuesday, a move that could result in a hefty fine for the U.S. pet products maker. Antitrust regulators on both…

The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. The RSI is a momentum ind...